Michael B Chancellor

List of Publications by Year
in descending order

256 papers	11,036 citations	18482 62 h-index	38395 95 g-index
272 all docs	272 docs citations	272 times ranked	5462 citing authors

#	Article	IF	Citations
1	Low energy shock wave therapy attenuates mitochondrial dysfunction and improves bladder function in HCl induced cystitis in rats. Biomedical Journal, 2022, 45, 482-490.	3.1	11
2	Long COVID and COVID-19-associated cystitis (CAC). International Urology and Nephrology, 2022, 54, 17-21.	1.4	18
3	Using social media to crowdsource collection of urine samples during a national pandemic. International Urology and Nephrology, 2022, 54, 493-498.	1.4	1
4	Editorial Comment. Journal of Urology, 2022, , 101097JU0000000000000244301.	0.4	0
5	Predictors of Poor Response and Adverse Events Following Botulinum Toxin A for Refractory Idiopathic Overactive Bladder: A Systematic Review. European Urology Focus, 2021, 7, 1448-1467.	3.1	12
6	Improves symptoms and urinary biomarkers in refractory interstitial cystitis/bladder pain syndrome patients randomized to extracorporeal shock wave therapy versus placebo. Scientific Reports, 2021, 11, 7558.	3.3	10
7	Improved global response outcome after intradetrusor injection of adult muscle-derived cells for the treatment of underactive bladder. International Urology and Nephrology, 2021, 53, 1331-1338.	1.4	6
8	Editorial Comment from Dr Chancellor to Decreased urothelial cytoskeleton and cell proliferation protein expression suggest interstitial cystitis/bladder pain syndrome patients with Hunnerâ€™s lesion and gradeÂ3 glomerulation might be different from other types of patients. International Journal of Urology, 2021, 28, 832-833.	1.0	0
9	Voiding defects in acute radiation cystitis driven by urothelial barrier defect through loss of E-cadherin, ZO-1 and Uroplakin III. Scientific Reports, 2021, 11, 19277.	3.3	7
10	Urinary Incontinence and Alzheimerâ€™s Disease: Insights From Patients and Preclinical Models. Frontiers in Aging Neuroscience, 2021, 13, 777819.	3.4	6
11	COVID-19 inflammation results in urine cytokine elevation and causes COVID-19 associated cystitis (CAC). Medical Hypotheses, 2020, 145, 110375.	1.5	52
12	Proteomic analysis of bladder biopsies from interstitial cystitis/bladder pain syndrome patients with and without Hunnerâ€™s lesions reveals differences in expression of inflammatory and structural proteins. BMC Urology, 2020, 20, 180.	1.4	8
13	Pain reduction realized with extracorporeal shock wave therapy for the treatment of symptoms associated with interstitial cystitis/bladder pain syndromeâ€”A prospective, multicenter, randomized, doubleâ€blind, placeboâ€controlled study. Neurourology and Urodynamics, 2020, 39, 1505-1514.	1.5	27
14	Correlation between lumbar skeletal muscle size and urinary incontinence after radical prostatectomy. LUTS: Lower Urinary Tract Symptoms, 2020, 12, 245-252.	1.3	7
15	Rapid detection of novel coronavirus/Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) by reverse transcription-loop-mediated isothermal amplification. PLoS ONE, 2020, 15, e0234682.	2.5	254
16	Radiation cystitis modeling: A comparative study of bladder fibrosis radioâ€sensitivity in C57BL/6, C3H, and BALB/c mice. Physiological Reports, 2020, 8, e14377.	1.7	17
17	Prostate cancer survivors with symptoms of radiation cystitis have elevated fibrotic and vascular proteins in urine. PLoS ONE, 2020, 15, e0241388.	2.5	10
18	De Novo Urinary Symptoms Associated With COVID-19: COVID-19-Associated Cystitis. Journal of Clinical Medicine Research, 2020, 12, 681-682.	1.2	34

#	Article	IF	Citations
19	Underactive Bladder; Review of Progress and Impact From the International CURE-UAB Initiative. International Neurourology Journal, 2020, 24, 3-11.	1.2	13
20	Micturition defects and altered bladder function in the mutant mouse model of aging. American Journal of Clinical and Experimental Urology, 2020, 8, 81-92.	0.4	4
21	Title is missing!. , 2020, 15, e0241388.		0
22	Title is missing!. , 2020, 15, e0241388.		0
23	Title is missing!. , 2020, 15, e0241388.		0
24	Title is missing!. , 2020, 15, e0241388.		0
25	Low Energy Shock Wave Therapy Inhibits Inflammatory Molecules and Suppresses Prostatic Pain and Hypersensitivity in a Capsaicin Induced Prostatitis Model in Rats. International Journal of Molecular Sciences, 2019, 20, 4777.	4.1	18
26	Translation, cross-cultural adaptation and validation of the underactive bladder questionnaire to portuguese. International Urology and Nephrology, 2019, 51, 1329-1334.	1.4	2
27	Long-term functional change of cryoinjury-induced detrusor underactivity and effects of extracorporeal shock wave therapy in a rat model. International Urology and Nephrology, 2019, 51, 617-626.	1.4	8
28	Use of Botulinum Toxin in the Genitourinary System. Handbook of Experimental Pharmacology, 2019, 263, 171-184.	1.8	4
29	Recent Developments in Imaging in BPS/IC. Current Bladder Dysfunction Reports, 2019, 14, 301-307.	0.5	0
30	Making a Case for Not Prescribing Antimuscarinic Drugs to Treat Overactive Bladder in Older Adults. Journal of Urology, 2019, 201, 676-677.	0.4	3
31	Radiation Cystitis Modeling: a Comparative Study of Bladder Radiationâ€Induced Fibrosis in Different Mouse Strains. FASEB Journal, 2019, 33, 366.1.	0.5	0
32	Rapid Detection of Zika Virus in Urine Samples and Infected Mosquitos by Reverse Transcription-Loop-Mediated Isothermal Amplification. Scientific Reports, 2018, 8, 3803.	3.3	50
33	Crowdsourcing Disease Biomarker Discovery Research: The IP4IC Study. Journal of Urology, 2018, 199, 1344-1350.	0.4	6
34	Pharmacological management of interstitial cystitis /bladder pain syndrome and the role cyclosporine and other immunomodulating drugs play. Expert Review of Clinical Pharmacology, 2018, 11, 495-505.	3.1	14
35	Urodynamic and molecular characteristics of detrusor underactivity in a rat cryoinjury model and effects of low energy shock wave therapy. Neurourology and Urodynamics, 2018, 37, 708-715.	1.5	14
36	Recent advances in imaging and understanding interstitial cystitis. F1000Research, 2018, 7, 1771.	1.6	23

#	Article	IF	Citations
37	Reverse Transcription-Loop-mediated Isothermal Amplification (RT-LAMP) Assay for Zika Virus and Housekeeping Genes in Urine, Serum, and Mosquito Samples. Journal of Visualized Experiments, 2018, , .	0.3	6
38	A double-blind, randomized, placebo-controlled clinical trial evaluating the safety and efficacy of autologous muscle derived cells in female subjects with stress urinary incontinence. International Urology and Nephrology, 2018, 50, 2153-2165.	1.4	37
39	Cancer survivorship issues with radiation and hemorrhagic cystitis in gynecological malignancies. International Urology and Nephrology, 2018, 50, 1745-1751.	1.4	25
40	New technology assessment and current and upcoming therapies for underactive bladder. Neurourology and Urodynamics, 2018, 37, 2932-2937.	1.5	7
41	Altered Angiogenic Growth Factors in Urine of Prostate Cancer Survivors With Radiation History and Radiation Cystitis. Urology, 2018, 120, 180-186.	1.0	5
42	Risk of Urinary Tract Carcinoma among Subjects with Bladder Pain Syndrome/Interstitial Cystitis: A Nationwide Population-Based Study. BioMed Research International, 2018, 2018, 1-7.	1.9	10
43	Patient characteristics for different therapeutic strategies in the management ketamine cystitis. Neurourology and Urodynamics, 2017, 36, 687-691.	1.5	22
44	Effect of Intravesical Liposome-Based Nerve Growth Factor Antisense Therapy on Bladder Overactivity and Nociception in a Rat Model of Cystitis Induced by Hydrogen Peroxide. Human Gene Therapy, 2017, 28, 598-609.	2.7	12
45	Editorial Comment. Journal of Urology, 2017, 197, 1495-1495.	0.4	0
46	Addressing challenges in underactive bladder: recommendations and insights from the Congress on Underactive Bladder (CURE-UAB). International Urology and Nephrology, 2017, 49, 777-785.	1.4	32
47	OnabotulinumtoxinA for Overactive Bladder and Urinary Incontinence. Journal of Urology, 2017, 197, S224-S225.	0.4	3
48	Development of an interstitial cystitis risk score for bladder permeability. PLoS ONE, 2017, 12, e0185686.	2.5	18
49	Health Resource Utilization and Cost for Patients with Incontinent Overactive Bladder Treated with Anticholinergics. Journal of Managed Care & Specialty Pharmacy, 2016, 22, 406-413.	0.9	22
50	Potential Effect of Liposomes and Liposome-Encapsulated Botulinum Toxin and Tacrolimus in the Treatment of Bladder Dysfunction. Toxins, 2016, 8, 81.	3.4	24
51	Ageâ€related changes in bladder function with altered angiotensin II receptor mechanisms in rats. Neurourology and Urodynamics, 2016, 35, 908-913.	1.5	5
52	Modeling of chronic radiation-induced cystitis in mice. Advances in Radiation Oncology, 2016, 1, 333-343.	1.2	28
53	Reply to the letter: Urine based molecular diagnosis of Zika virus by Viroj Wiwanitkit. International Urology and Nephrology, 2016, 48, 2025-2025.	1.4	1
54	Patientâ€reported goal achievement following onabotulinumtoxinA treatment in patients with neurogenic detrusor overactivity. Neurourology and Urodynamics, 2016, 35, 595-600.	1.5	10

#	Article	IF	Citations
55	Advantage of urine based molecular diagnosis of Zika virus. International Urology and Nephrology, 2016, 48, 1961-1966.	1.4	22
56	A cross-sectional study in the USA of the epidemiology and quality of life of underactive bladder symptoms. International Urology and Nephrology, 2016, 48, 1797-1802.	1.4	19
57	Elevated CXC chemokines in urine noninvasively discriminate OAB from UTI. American Journal of Physiology - Renal Physiology, 2016, 311, F548-F554.	2.7	24
58	Anandamide transporter-mediated regulation of the micturition reflex in urethane-anesthetized rats. International Urology and Nephrology, 2016, 48, 1407-1412.	1.4	7
59	Bladder overactivity involves overexpression of MicroRNA 132 and nerve growth factor. Life Sciences, 2016, 167, 98-104.	4.3	12
60	Limitations of anticholinergic cycling in patients with overactive bladder (OAB) with urinary incontinence (UI): results from the CONsequences of Treatment Refractory Overactive bLadder (CONTROL) study. International Urology and Nephrology, 2016, 48, 1029-1036.	1.4	37
61	Use of Botulinum Toxin in Urologic Diseases. Urology, 2016, 91, 21-32.	1.0	16
62	Modeling and Treatment of Radiation Cystitis. Urology, 2016, 88, 14-21.	1.0	41
63	Spinal glycine transporter-1 inhibition influences the micturition reflex in urethane-anesthetized rats. International Urology and Nephrology, 2016, 48, 349-354.	1.4	0
64	Liposome Based Intravesical Therapy Targeting Nerve Growth Factor Ameliorates Bladder Hypersensitivity in Rats with Experimental Colitis. Journal of Urology, 2016, 195, 1920-1926.	0.4	25
65	Botulinum Toxin to Treat Neurogenic Bladder. Seminars in Neurology, 2016, 36, 005-009.	1.4	11
66	Pathophysiology and Animal Modeling of Underactive Bladder. , 2016, , 51-68.		1
67	Role of the Anterior Cingulate Cortex in the Control of Micturition Reflex in a Rat Model of Parkinson's Disease. Journal of Urology, 2016, 195, 1613-1620.	0.4	24
68	Challenges and Opportunities in Radiation-induced Hemorrhagic Cystitis. Reviews in Urology, 2016, 18, 57-65.	0.9	17
69	Surgery for Underactive Bladder Treatment. , 2016, , 135-154.		0
70	Epidemiology and Demographics of Underactive Bladder. , 2016, , 1-11.		1
71	Effect of Sacral Neuromodulation on Outcome Measures and Urine Chemokines in Interstitial Cystitis/Painful Bladder Syndrome Patients. LUTS: Lower Urinary Tract Symptoms, 2015, 7, 77-83.	1.3	14
72	Bladder Uptake of Liposomes after Intravesical Administration Occurs by Endocytosis. PLoS ONE, 2015, 10, e0122766.	2.5	33

#	Article	IF	Citations
73	Effects of Duloxetine on Urethral Continence Reflex and Bladder Activity in Rats with Cerebral Infarction. Journal of Urology, 2015, 194, 842-847.	0.4	12
74	Underactive Bladder in Older Adults. Clinics in Geriatric Medicine, 2015, 31, 523-533.	2.6	18
75	Intradetrusor injection of adult muscle-derived cells for the treatment of underactive bladder: pilot study. International Urology and Nephrology, 2015, 47, 465-467.	1.4	40
76	Clinical Efficacy and Tolerability of the Nicotinic Channel Modulator Dexmecamylamine in Subjects with Overactive Bladder. Journal of Urology, 2015, 194, 1329-1335.	0.4	1
77	Pharmacologic and Molecular Characterization of Underactive Bladder Induced by Lumbar Canal Stenosis. Urology, 2015, 85, 1284-1290.	1.0	8
78	Intravesical Liposomal Tacrolimus Protects against Radiation Cystitis Induced by 3-Beam Targeted Bladder Radiation. Journal of Urology, 2015, 194, 578-584.	0.4	38
79	Use of botulinum toxin for genitourinary conditions: What is the evidence?. Toxicon, 2015, 107, 141-147.	1.6	10
80	Innovative use of intravesical tacrolimus for hemorrhagic radiation cystitis. International Urology and Nephrology, 2015, 47, 1679-1681.	1.4	19
81	Building momentum toward underactive bladder research and education. International Urology and Nephrology, 2015, 47, 1593-1594.	1.4	1
82	Current and emerging drugs for interstitial cystitis/bladder pain syndrome (IC/BPS). Expert Opinion on Emerging Drugs, 2015, 20, 555-570.	2.4	28
83	Effect of botulinum toxin A on urothelial-release of ATP and expression of SNARE targets within the urothelium. Neurourology and Urodynamics, 2015, 34, 79-84.	1.5	61
84	Presence of Cleaved Synaptosomal-Associated Protein-25 and Decrease of Purinergic Receptors P2X3 in the Bladder Urothelium Influence Efficacy of Botulinum Toxin Treatment for Overactive Bladder Syndrome. PLoS ONE, 2015, 10, e0134803.	2.5	14
85	Best of the 2015 AUA Annual Meeting: Highlights From the 2015 American Urological Association Annual Meeting, May 15-19, 2015, New Orleans, LA. Reviews in Urology, 2015, 17, 179-89.	0.9	0
86	Intravesical liposome drug delivery and IC/BPS. Translational Andrology and Urology, 2015, 4, 572-8.	1.4	5
87	Functional and Molecular Characterization of Hyposensitive Underactive Bladder Tissue and Urine in Streptozotocin-Induced Diabetic Rat. PLoS ONE, 2014, 9, e102644.	2.5	33
88	Epidemiology and demographics of the underactive bladder: a cross-sectional survey. International Urology and Nephrology, 2014, 46, 7-10.	1.4	42
89	CURE-UAB: shedding light on the underactive bladder syndrome. International Urology and Nephrology, 2014, 46, 1-1.	1.4	16
90	Defining and advancing education and conservative therapies of underactive bladder. International Urology and Nephrology, 2014, 46, 29-34.	1.4	6

#	Article	IF	Citations
91	Advanced therapeutic directions to treat the underactive bladder. International Urology and Nephrology, 2014, 46, 35-44.	1.4	16
92	Intravesical Liposome and Antisense Treatment for Detrusor Overactivity and Interstitial Cystitis/Painful Bladder Syndrome. ISRN Pharmacology, 2014, 2014, 1-12.	1.6	11
93	Liposomal bladder instillations for IC/BPS: an open-label clinical evaluation. International Urology and Nephrology, 2014, 46, 2291-2295.	1.4	36
94	Statinâ€Associated Underactive Bladder. LUTS: Lower Urinary Tract Symptoms, 2014, 6, 124-125.	1.3	2
95	Advances in Therapeutic Development for Radiation Cystitis. LUTS: Lower Urinary Tract Symptoms, 2014, 6, 1-10.	1.3	18
96	The overactive bladder progression to underactive bladder hypothesis. International Urology and Nephrology, 2014, 46, 23-27.	1.4	76
97	Pathophysiology and animal modeling of underactive bladder. International Urology and Nephrology, 2014, 46, 11-21.	1.4	54
98	Neural Mechanisms Underlying Lower Urinary Tract Dysfunction. Korean Journal of Urology, 2014, 55, 81.	1.2	26
99	Pilot Study of Liposome-encapsulated OnabotulinumtoxinA for Patients with Overactive Bladder: A Single-center Study. European Urology, 2014, 65, 1117-1124.	1.9	100
100	Association of inflammaging (inflammationÂ+Âaging) with higher prevalence of OAB in elderly population. International Urology and Nephrology, 2014, 46, 871-877.	1.4	45
101	Bladder Instillation of Liposome Encapsulated OnabotulinumtoxinA Improves Overactive Bladder Symptoms: A Prospective, Multicenter, Double-Blind, Randomized Trial. Journal of Urology, 2014, 192, 1743-1749.	0.4	88
102	Autologous Muscle Derived Cells for Treatment of Stress Urinary Incontinence in Women. Journal of Urology, 2014, 192, 469-476.	0.4	108
103	Optimum Management of Overactive Bladder: Medication vs Botox ^{Â®} vs InterStim ^{Â®} vs Urgent ^{Â®} PC. Urology Practice, 2014, 1, 7-12.	0.5	6
104	Update in the Use of Botulinum Toxin for the Treatment of Benign Prostatic Hyperplasia/ Lower Urinary Tract Symptoms. Current Bladder Dysfunction Reports, 2013, 8, 174-179.	0.5	2
105	Intravesical drug delivery for dysfunctional bladder. International Journal of Urology, 2013, 20, 552-562.	1.0	48
106	Autologous Muscle Derived Cell Therapy for Stress Urinary Incontinence: A Prospective, Dose Ranging Study. Journal of Urology, 2013, 189, 595-601.	0.4	118
107	Long-Term Patterns of Use and Treatment Failure With Anticholinergic Agents for Overactive Bladder. Clinical Therapeutics, 2013, 35, 1744-1751.	2.5	100
108	Down-Regulation of Nerve Growth Factor Expression in the Bladder by Antisense Oligonucleotides as New Treatment for Overactive Bladder. Journal of Urology, 2013, 190, 757-764.	0.4	47

#	Article	IF	Citations
109	Development of Potential Orphan Drug Therapy of Intravesical Liposomal Tacrolimus for Hemorrhagic Cystitis Due to Increased Local Drug Exposure. Journal of Urology, 2013, 189, 1553-1558.	0.4	25
110	Evidence-based review and assessment of botulinum neurotoxin for the treatment of urologic conditions. Toxicon, 2013, 67, 129-140.	1.6	30
111	Future Direction in Pharmacotherapy for Non-neurogenic Male Lower Urinary Tract Symptoms. European Urology, 2013, 64, 610-621.	1.9	50
112	OnabotulinumtoxinA improves quality of life in patients with neurogenic detrusor overactivity. Neurology, 2013, 81, 841-848.	1.1	47
113	OnobotulinumtoxinA Has No Effects on Growth of LNCaP and PC3 Human Prostate Cancer Cells. LUTS: Lower Urinary Tract Symptoms, 2013, 5, 168-172.	1.3	4
114	Development and Validation of the Actionable Bladder Symptom Screening Tool for Multiple Sclerosis Patients. International Journal of MS Care, 2013, 15, 182-192.	1.0	39
115	The other bladder syndrome: underactive bladder. Reviews in Urology, 2013, 15, 11-22.	0.9	100
116	Anticholinergics for Overactive Bladder Therapy: Central Nervous System Effects. CNS Neuroscience and Therapeutics, 2012, 18, 167-174.	3.9	95
117	Urinary Chemokines as Noninvasive Predictors of Ulcerative Interstitial Cystitis. Journal of Urology, 2012, 187, 2243-2248.	0.4	89
118	Bloodâ€“Brain Barrier Permeation and Efflux Exclusion of Anticholinergics Used in the Treatment of Overactive Bladder. Drugs and Aging, 2012, 29, 259-273.	2.7	88
119	Editorial Comment from Dr Chancellor to Periurethral injection of autologous adiposeâ€derived regenerative cells for the treatment of male stress urinary incontinence: Report of three initial cases. International Journal of Urology, 2012, 19, 661-661.	1.0	0
120	Association of overactive bladder and Câ€reactive protein levels. Results from the Boston Area Community Health (BACH) Survey. BJU International, 2012, 110, 401-407.	2.5	32
121	Physiology and Pharmacology of the Bladder and Urethra. , 2012, , 1786-1833.e17.		22
122	Mirabegron: a safety review. Expert Opinion on Drug Safety, 2011, 10, 287-294.	2.4	41
123	Promise of Urinary Nerve Growth Factor for Assessment of Overactive Bladder Syndrome. LUTS: Lower Urinary Tract Symptoms, 2011, 3, 2-9.	1.3	9
124	Nerve growth factor level in the prostatic fluid of patients with chronic prostatitis/chronic pelvic pain syndrome is correlated with symptom severity and response to treatment. BJU International, 2011, 108, 248-251.	2.5	55
125	Development of cellular therapy for the treatment of stress urinary incontinence. International Urogynecology Journal, 2011, 22, 1075-1083.	1.4	40
126	Neurotoxin Use for Voiding Dysfunction. Current Bladder Dysfunction Reports, 2011, 6, 182-189.	0.5	0

#	Article	IF	Citations
127	Intravesical immune suppression by liposomal tacrolimus in cyclophosphamideâ€induced inflammatory cystitis. Neurourology and Urodynamics, 2011, 30, 421-427.	1.5	36
128	Botulinum Toxin Injection for Prostate Disorders. , 2011, , 111-130.		0
129	Overactive Bladder and Idiopathic Detrusor Overactivity. , 2011, , 61-78.		0
130	Obesity is associated with a more severe overactive bladder disease state that is effectively treated with onceâ€daily administration of trospium chloride extended release. Neurourology and Urodynamics, 2010, 29, 551-554.	1.5	22
131	Ten years single surgeon experience with botulinum toxin in the urinary tract; clinical observations and research discovery. International Urology and Nephrology, 2010, 42, 383-391.	1.4	20
132	Urine cytokines suggest an inflammatory response in the overactive bladder: a pilot study. International Urology and Nephrology, 2010, 42, 629-635.	1.4	146
133	Dynamic Progression of Overactive Bladder and Urinary Incontinence Symptoms: A Systematic Review. European Urology, 2010, 58, 532-543.	1.9	87
134	Urinary nerve growth factor but not prostaglandin E2 increases in patients with interstitial cystitis/bladder pain syndrome and detrusor overactivity. BJU International, 2010, 106, 1681-1685.	2.5	92
135	Botulinum toxin for the lower urinary tract. BJU International, 2010, 105, 1046-1058.	2.5	27
136	Efficacy and Safety of OnabotulinumtoxinA for Idiopathic Overactive Bladder: A Double-Blind, Placebo Controlled, Randomized, Dose Ranging Trial. Journal of Urology, 2010, 184, 2416-2422.	0.4	352
137	Urinary Nerve Growth Factor Levels in Urinary Tract Diseases With or Without Frequency Urgency Symptoms. LUTS: Lower Urinary Tract Symptoms, 2010, 2, 88-94.	1.3	31
138	PP-436 ãƒ©ãƒƒãƒˆæŽ’å°¿å¾Œå°„ã«å¯¾ã™ã‚‹galaninã®å½¹å‰²(ç™ºè¡¨ãƒ»è¨Žè«–,ç¬¬98å›žæ—¥æœ¬æ³Œå°¿å™¨çš®å¦¼ç§‘å¦šä¼š). Japan		
139	State of the art in intravesical therapy for lower urinary tract symptoms. Reviews in Urology, 2010, 12, e181-9.	0.9	12
140	Investigations into the presence of functional ÃŸ1, ÃŸ2 and ÃŸ3-adrenoceptors in urothelium and detrusor of human bladder. International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2009, 35, 76-83.	1.5	64
141	Urinary Nerve Growth Factor Levels are Elevated in Patients with Detrusor Overactivity and Decreased in Responders to Detrusor Botulinum Toxin-A Injection. European Urology, 2009, 56, 700-707.	1.9	163
142	Intravesical Botulinum Toxin A Administration Inhibits COX-2 and EP4 Expression and Suppresses Bladder Hyperactivity in Cyclophosphamide-Induced Cystitis in Rats. European Urology, 2009, 56, 159-167.	1.9	84
143	Transabdominal Ultrasound Measurement of Detrusor Wall Thickness in Patients with Overactive Bladder. Tzu Chi Medical Journal, 2009, 21, 129-135.	1.1	9
144	Cystometric Changes in Pressure-guided Acute Distension Rat Model of the Underactive Bladderâ„¢. Tzu Chi Medical Journal, 2009, 21, 136-139.	1.1	2

#	Article	IF	Citations
145	Decrease of urinary nerve growth factor levels after antimuscarinic therapy in patients with overactive bladder. BJU International, 2009, 103, 1668-1672.	2.5	101
146	Comparison of intravesical botulinum toxin type A injections plus hydrodistention with hydrodistention alone for the treatment of refractory interstitial cystitis/painful bladder syndrome. BJU International, 2009, 104, 657-661.	2.5	166
147	Urinary nerve growth factor level is correlated with the severity of neurological impairment in patients with cerebrovascular accident. BJU International, 2009, 104, 1158-1162.	2.5	25
148	Urinary nerve growth factor level is increased in patients with interstitial cystitis/bladder pain syndrome and decreased in responders to treatment. BJU International, 2009, 104, 1476-1481.	2.5	118
149	Multiplex Analysis of Urinary Cytokine Levels in Rat Model of Cyclophosphamide-induced Cystitis. Urology, 2009, 73, 421-426.	1.0	75
150	Diabetes-induced Alternations in Biomechanical Properties of Urinary Bladder Wall in Rats. Urology, 2009, 73, 911-915.	1.0	39
151	Bladder Botulinum Toxin. LUTS: Lower Urinary Tract Symptoms, 2009, 1, S22.	1.3	1
152	Role of Sarco/Endoplasmic Reticulum Calcium ATPase in Lower Urinary Tract Smooth Muscles. LUTS: Lower Urinary Tract Symptoms, 2009, 1, S50.	1.3	2
153	Novel Biomarkers for Diagnosis and Therapeutic Assessment of Overactive Bladder: Urinary Nerve Growth Factor and Detrusor Wall Thickness. LUTS: Lower Urinary Tract Symptoms, 2009, 1, S59.	1.3	0
154	Muscleâ€derived Stem Cell Therapy for Stress Urinary Incontinence. LUTS: Lower Urinary Tract Symptoms, 2009, 1, S62.	1.3	0
155	Noninvasive Videourodynamics Using Transperineal Doppler Ultrasonography. LUTS: Lower Urinary Tract Symptoms, 2009, 1, S80.	1.3	0
156	Lower Urinary Tract: Diabetes Mellitusâ€focused on Recent Experimental Results. LUTS: Lower Urinary Tract Symptoms, 2009, 1, S87.	1.3	1
157	Bladder Instillation of Liposomes for Bladder Coating and Drug Delivery Platform. LUTS: Lower Urinary Tract Symptoms, 2009, 1, S90.	1.3	2
158	Biomechanics of Diabetic Bladders. LUTS: Lower Urinary Tract Symptoms, 2009, 1, S94.	1.3	0
159	Gene Therapy for Neurogenic Erectile Dysfunction. LUTS: Lower Urinary Tract Symptoms, 2009, 1, S44.	1.3	0
160	Urodynamic and Immunohistochemical Evaluation of Intravesical Botulinum Toxin A Delivery Using Liposomes. Journal of Urology, 2009, 182, 786-792.	0.4	118
161	OP-051 è„Šé«„æè‚·ãƒ©ãƒƒãƒˆã«ãŠã‘ã‚‹è„Šé«„ã‚¢ãƒ‰ãƒŠãƒªãƒ³Î±1å•–å®³ä½“é®æ––è–¬ã®æŽ’å°¿æŠ‘åˆ¶ä½œç”(Neurourology/		
162	IL4 Botulinum Toxin for LUTS Past, Present and Future(The 97th Annual Meeting of the Japanese) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 6	0.1	0

#	Article	IF	Citations
163	Physiological effects of human muscle-derived stem cell implantation on urethral smooth muscle function. International Urogynecology Journal, 2008, 19, 1229-1234.	1.4	17
164	Bladder botulinum toxin A injection can benefit patients with radiation and chemical cystitis. BJU International, 2008, 102, 704-706.	2.5	50
165	Urinary nerve growth factor level could be a biomarker in the differential diagnosis of mixed urinary incontinence in women. BJU International, 2008, 102, 080516035452788-???.	2.5	54
166	Neurotoxin Versus Neuromodulation for the Treatment of Refractory Overactive Bladder Syndrome. Tzu Chi Medical Journal, 2008, 20, 109-111.	1.1	1
167	Intraprostatic Botulinum Toxin A Injection Inhibits Cyclooxygenase-2 Expression and Suppresses Prostatic Pain on Capsaicin Induced Prostatitis Model in Rat. Journal of Urology, 2008, 180, 742-748.	0.4	84
168	Proteomic Investigation on Chronic Bladder Irritation in the Rat. Urology, 2008, 71, 536-540.	1.0	9
169	Time-Dependent Alterations of Select Genes in Streptozotocin-Induced Diabetic Rat Bladder. Urology, 2008, 71, 1214-1219.	1.0	20
170	Case for Pharmacotherapy Development for Underactive Bladder. Urology, 2008, 72, 966-967.	1.0	42
171	Efficacy of solifenacin in patients previously treated with tolterodine extended release 4 mg: Results of a 12-week, multicenter, open-label, flexible-dose study. Clinical Therapeutics, 2008, 30, 1766-1781.	2.5	49
172	A PILOT STUDY OF AAV1/SERCA2a GENE TRANSFER IN THE RAT STRESS URINARY INCONTINENCE MODEL. Journal of Urology, 2008, 179, 534-535.	0.4	3
173	Association of overactive bladder and stress urinary incontinence in rats with pudendal nerve ligation injury. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2008, 294, R1510-R1516.	1.8	21
174	Drug Insight: biological effects of botulinum toxin A in the lower urinary tract. Nature Reviews Urology, 2008, 5, 319-328.	1.4	108
175	Diagnosis of incontinence. Reviews in Urology, 2008, 10, 242-3.	0.9	0
176	Is behavioral therapy plus antimuscarinic better than drug alone to treat overactive bladder?. Reviews in Urology, 2008, 10, 306-8.	0.9	3
177	Role of noradrenergic pathways in sneeze-induced urethral continence reflex in rats. American Journal of Physiology - Renal Physiology, 2007, 292, F639-F646.	2.7	58
178	Human muscleâ€derived cell injection in a rat model of stress urinary incontinence. Muscle and Nerve, 2007, 36, 391-393.	2.2	22
179	Intraprostatic Capsaicin Injection as a Novel Model for Nonbacterial Prostatitis and Effects of Botulinum Toxin A. European Urology, 2007, 51, 1119-1127.	1.9	67
180	The promise of stem cell therapy to restore urethral sphincter function. Current Urology Reports, 2007, 8, 373-378.	2.2	14

#	Article	IF	Citations
181	Treatment of overactive bladder: selective use of anticholinergic agents with low drug-drug interaction potential. Geriatrics, 2007, 62, 15-24.	0.3	11
182	Qualitative and Quantitative Expression Profile of Muscarinic Receptors in Human Urothelium and Detrusor. Journal of Urology, 2006, 176, 1673-1678.	0.4	95
183	The Application of Botulinum Toxin in the Prostate. Journal of Urology, 2006, 176, 2375-2382.	0.4	80
184	Novel Action of Botulinum Toxin on the Stromal and Epithelial Components of the Prostate Gland. Journal of Urology, 2006, 175, 1158-1163.	0.4	141
185	Functional Analysis of Active Urethral Closure Mechanisms Under Sneeze Induced Stress Condition in a Rat Model of Birth Trauma. Journal of Urology, 2006, 176, 2711-2715.	0.4	50
186	The Overactive Bladder: Epidemiology and Morbidity. Urologic Clinics of North America, 2006, 33, 433-438.	1.8	36
187	Periurethral cellular injection: Comparison of muscle-derived progenitor cells and fibroblasts with regard to efficacy and tissue contractility in an animal model of stress urinary incontinence. Urology, 2006, 68, 449-454.	1.0	117
188	Pharmacotherapy for Neurogenic Detrusor Overactivity. American Journal of Physical Medicine and Rehabilitation, 2006, 85, 536-545.	1.4	92
189	Sustained beneficial effects of intraprostatic botulinum toxin type A on lower urinary tract symptoms and quality of life in men with benign prostatic hyperplasia. BJU International, 2006, 98, 1033-1037.	2.5	102
190	Botulinum: A toxin for the treatment of benign prostatic hyperplasia/lower urinary tract symptoms. Current Prostate Reports, 2006, 4, 75-80.	0.1	0
191	Recent advances in understanding the biology of diabetes-associated bladder complications and novel therapy. BJU International, 2005, 95, 733-738.	2.5	153
192	Pittsburgh experience with lower urinary tract botulinum toxin a injectionmichael. Current Urology Reports, 2005, 6, 235-236.	2.2	0
193	Recent advances in the neurophysiology of stress urinary incontinence. Scandinavian Journal of Urology and Nephrology, 2005, 39, 21-24.	1.4	46
194	Simplified Bladder Botulinum-Toxin Delivery Technique Using Flexible Cystoscope and 10 Sites of Injection. Journal of Endourology, 2005, 19, 880-882.	2.1	53
195	Single-institution experience in 110 patients with botulinum toxin A injection into bladder or urethra. Urology, 2005, 65, 37-41.	1.0	183
196	Botulinum toxin type A improves benign prostatic hyperplasia symptoms in patients with small prostates. Urology, 2005, 66, 775-779.	1.0	114
197	Detrusor overactivity induced by intravesical application of adenosine 5â€²-triphosphate under different delivery conditions in rats. Urology, 2005, 66, 1332-1337.	1.0	53
198	Î± ₁ -ADRENERGIC MECHANISM IN DIABETIC URETHRAL DYSFUNCTION IN RATS. Journal of Urology, 2005, 173, 1027-1032.	0.4	36

#	Article	IF	Citations
199	Tissue Engineering to Rebuild the Lower Urinary Tract. Japanese Journal of Urology, 2005, 96, 54-55.	0.1	0
200	Treatment of stress urinary incontinence with duloxetine hydrochloride. Reviews in Urology, 2005, 7, 81-6.	0.9	13
201	Gene Therapy Using Replication-Defective Herpes Simplex Virus Vectors Expressing Nerve Growth Factor in a Rat Model of Diabetic Cystopathy. Diabetes, 2004, 53, 2723-2730.	0.6	92
202	Urodynamic and Immunohistochemical Evaluation of Intravesical Capsaicin Delivery Using Thermosensitive Hydrogel and Liposomes. Journal of Urology, 2004, 171, 483-489.	0.4	65
203	Urethral Dysfunction in Diabetic Rats. Journal of Urology, 2004, 171, 1959-1964.	0.4	81
204	INTRAVESICAL BOTULINUM TOXIN A ADMINISTRATION PRODUCES ANALGESIA AGAINST ACETIC ACID INDUCED BLADDER PAIN RESPONSES IN RATS. Journal of Urology, 2004, 172, 1529-1532.	0.4	242
205	Suppression of Detrusor-Sphincter Dyssynergia by Immunoneutralization of Nerve Growth Factor in Lumbosacral Spinal Cord in Spinal Cord Injured Rats. Journal of Urology, 2004, 171, 478-482.	0.4	107
206	EMERGING ROLE OF BOTULINUM TOXIN IN THE MANAGEMENT OF VOIDING DYSFUNCTION. Journal of Urology, 2004, 171, 2128-2137.	0.4	176
207	Treatment of interstitial cystitis. Urology, 2004, 63, 85-92.	1.0	107
208	Intraurethral muscle-derived cell injections increase leak point pressure in a rat model of intrinsic sphincter deficiency. Urology, 2004, 63, 780-785.	1.0	107
209	Botulinum toxin a has antinociceptive effects in treating interstitial cystitis. Urology, 2004, 64, 871-875.	1.0	255
210	The role of bladder-to-urethral reflexes in urinary continence mechanisms in rats. American Journal of Physiology - Renal Physiology, 2004, 287, F434-F441.	2.7	86
211	Implications of diabetes mellitus in urology. Urologic Clinics of North America, 2003, 30, 1-12.	1.8	89
212	Effect of Botulinum Toxin A on the Autonomic Nervous System of the Rat Lower Urinary Tract. Journal of Urology, 2003, 169, 1896-1900.	0.4	168
213	Improved sphincter contractility after allogenic muscle-derived progenitor cell injection into the denervated rat urethra. Urology, 2003, 62, 958-963.	1.0	157
214	Effect of stimulation intensity and botulinum toxin isoform on rat bladder strip contractions. Brain Research Bulletin, 2003, 61, 165-171.	3.0	62
215	Transdermal Oxybutynin. Drugs and Aging, 2003, 20, 865-866.	2.7	0
216	Urethral closure mechanisms under sneeze-induced stress condition in rats: a new animal model for evaluation of stress urinary incontinence. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2003, 285, R356-R365.	1.8	103

#	Article	IF	Citations
217	New Frontiers in the Treatment of Overactive Bladder. Journal of the Korean Continence Society, 2003, 7, 1.	0.1	0
218	Immunoneutralization of Nerve Growth Factor in Lumbosacral Spinal Cord Reduces Bladder Hyperreflexia in Spinal Cord Injured Rats.. Journal of Urology, 2002, 168, 2269-2274.	0.4	176
219	Effect of cryoinjury on the contractile parameters of bladder strips: A model of impaired detrusor contractility. Brain Research Bulletin, 2002, 59, 23-28.	3.0	34
220	Diabetic Cystopathy Correlates With a Long-Term Decrease in Nerve Growth Factor Levels in The Bladder and Lumbosacral Dorsal Root Ganglia. Journal of Urology, 2002, 168, 1259-1264.	0.4	116
221	Passive Biaxial Mechanical Properties of the Rat Bladder Wall After Spinal Cord Injury. Journal of Urology, 2002, 167, 2247-2252.	0.4	67
222	Botulinum Toxin Urethral Sphincter Injection to Restore Bladder Emptying in a Woman With Multiple Sclerosis. International Journal of MS Care, 2002, 4, 70-72.	1.0	4
223	Urologic Applications of Botulium Toxin. Journal of the Korean Continence Society, 2002, 6, 22.	0.1	0
224	Diabetic cystopathy correlates with a long-term decrease in nerve growth factor levels in the bladder and lumbosacral dorsal root Ganglia. Journal of Urology, 2002, 168, 1259-64.	0.4	47
225	THE ROLE OF BLADDER AFFERENT PATHWAYS IN BLADDER HYPERACTIVITY INDUCED BY THE INTRAVESICAL ADMINISTRATION OF NERVE GROWTH FACTOR. Journal of Urology, 2001, 165, 975-979.	0.4	138
226	BOTULINUM TOXIN URETHRAL SPHINCTER INJECTION TO RESTORE BLADDER EMPTYING IN MEN AND WOMEN WITH VOIDING DYSFUNCTION. Journal of Urology, 2001, 165, 1107-1110.	0.4	202
227	PERSISTENCE AND SURVIVAL OF AUTOLOGOUS MUSCLE DERIVED CELLS VERSUS BOVINE COLLAGEN AS POTENTIAL TREATMENT OF STRESS URINARY INCONTINENCE. Journal of Urology, 2001, 165, 271-276.	0.4	100
228	HERPES SIMPLEX VIRUS MEDIATED NERVE GROWTH FACTOR EXPRESSION IN BLADDER AND AFFERENT NEURONS: POTENTIAL TREATMENT FOR DIABETIC BLADDER DYSFUNCTION. Journal of Urology, 2001, 165, 1748-1754.	0.4	96
229	Urodynamic monitoring during percutaneous sacral nerve neurostimulation in patients with neurogenic detrusor hyperreflexia. Neurourology and Urodynamics, 2001, 20, 61-71.	1.5	40
230	Genitourinary tract patent update. Expert Opinion on Therapeutic Patents, 2001, 11, 17-31.	5.0	6
231	Autologous Primary Muscle-Derived Cells Transfer into the Lower Urinary Tract. Tissue Engineering, 2001, 7, 395-404.	4.6	58
232	Preliminary results of myoblast injection into the urethra and bladder wall: A possible method for the treatment of stress urinary incontinence and impaired detrusor contractility. Neurourology and Urodynamics, 2000, 19, 279-287.	1.5	177
233	Principles of Sacral Nerve Stimulation (SNS) for the Treatment of Bladder and Urethral Sphincter Dysfunctions. Neuromodulation, 2000, 3, 15-26.	0.8	94
234	Myoblast therapy for stress urinary incontinence and bladder dysfunction. World Journal of Urology, 2000, 18, 56-61.	2.2	67

#	Article	IF	Citations
235	DISCUSSION: RESINIFERATOXIN-PRELIMINARY DATA. BJU International, 2000, 85, 65-65.	2.5	1
236	LONG-TERM RESULTS OF SACRAL NERVE STIMULATION (S3) FOR THE TREATMENT OF NEUROGENIC REFRACTORY URGE INCONTINENCE RELATED TO DETRUSOR HYPERREFLEXIA. Journal of Urology, 2000, 164, 1476-1480.	0.4	156
237	EFFECT OF INTRAVESICAL NITRIC OXIDE THERAPY ON CYCLOPHOSPHAMIDE-INDUCED CYSTITIS. Journal of Urology, 1999, 162, 2211-2216.	0.4	124
238	URETHRAL AFFERENT NERVE ACTIVITY AFFECTS THE MICTURITION REFLEX; IMPLICATION FOR THE RELATIONSHIP BETWEEN STRESS INCONTINENCE AND DETRUSOR INSTABILITY. Journal of Urology, 1999, 162, 204-212.	0.4	225
239	DEVELOPMENT OF NONINVASIVE VELOCITY FLOW VIDEO URODYNAMICS USING DOPPLER SONOGRAPHY. PART I: EXPERIMENTAL URETHRA. Journal of Urology, 1998, 160, 1787-1791.	0.4	23
240	DEVELOPMENT OF NONINVASIVE VELOCITY FLOW VIDEO URODYNAMICS USING DOPPLER SONOGRAPHY. PART II: CLINICAL APPLICATION IN BLADDER OUTLET OBSTRUCTION. Journal of Urology, 1998, 160, 1792-1796.	0.4	35
241	In-Vivo Whole Bladder Response to Anticholinergic and Musculotropic Agents in Spinal Cord Injured Rats. Journal of Spinal Cord Medicine, 1997, 20, 31-35.	1.4	5
242	EDITORIAL: SHOULD WE BE USING CHILI PEPPER EXTRACTS TO TREAT THE OVERACTIVE BLADDER?. Journal of Urology, 1997, 158, 2097-2097.	0.4	8
243	Gracilis urethromyoplasty â€“ an autologous urinary sphincter for neurologically impaired patients with stress incontinence. Spinal Cord, 1997, 35, 546-549.	1.9	8
244	Gracilis muscle transposition with electrical stimulation for sphincteric incontinence: a new approach. World Journal of Urology, 1997, 15, 320-328.	2.2	9
245	Uroflowmetry. , 0, , 37-45.		0
246	Leak Point Pressure. , 0, , 46-55.		1
247	Normal Micturition. , 0, , 11-21.		2
248	Pre-Urodynamic Evaluation. , 0, , 1-10.		0
249	Bladder Outlet Obstruction and Impaired Detrusor Contractility in Women. , 0, , 120-144.		0
250	Genital Prolapse. , 0, , 197-211.		0
251	Sphincteric Incontinence in Men and Other Complications of Prostate Cancer Treatment. , 0, , 212-226.		0
252	Enterocystoplasty and Neobladder. , 0, , 227-234.		0

#	Article	IF	Citations
253	Cystometry. , 0, , 22-36.		0
254	Low Bladder Compliance. , 0, , 56-61.		1
255	Pitfalls in Interpretation of Urodynamic Studies. , 0, , 69-82.		0
256	Overactive Bladder. , 0, , 83-95.		0